<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05100654</url>
  </required_header>
  <id_info>
    <org_study_id>IRB19-1757</org_study_id>
    <nct_id>NCT05100654</nct_id>
  </id_info>
  <brief_title>Collaborative Urological Prosthetics Investigation Directive Research Group</brief_title>
  <acronym>CUPID</acronym>
  <official_title>Collaborative Urological Prosthetics Investigation Directive Research Group</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Loyola University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if an additional 6 days of oral antibiotics&#xD;
      decreases the risk of penile prosthesis infection after implantation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 30, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Additional 6 days of oral antibiotics after Penile prothesis placement does not decrease the risk of device infection leading to surgical intervention</measure>
    <time_frame>12 months</time_frame>
    <description>From day of surgery through 1 year we are hoping to show that additional 6 days of oral antibiotics do not decrease the risk of penile prosthesis infection requiring surgical intervention for device removal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Additional 6 days of oral antibiotics after Penile prosthesis placement does not decrease the risk of superficial tissue infections after penile prothesis implantation.</measure>
    <time_frame>12 months</time_frame>
    <description>From day of surgery through 1 year we are hoping to show that additional 6 days of oral antibiotics do not decrease the risk of superficial skin infection after penile prosthesis placement.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Erectile Dysfunction</condition>
  <condition>Penile Prosthesis Infection</condition>
  <arm_group>
    <arm_group_label>No post-operative oral antibiotics</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will only receive 24hr of IV peri-operative antibiotics</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6 days of oral antibiotics</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive 24hr of IV peri-operative antibiotics and then 6 days of oral antibiotics</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline</intervention_name>
    <description>Patients will be given 6 days of oral antibiotics based on local biograms, patient allergies and renal and liver function</description>
    <arm_group_label>6 days of oral antibiotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin</intervention_name>
    <description>Patients will be given 6 days of oral antibiotics based on local biograms, patient allergies and renal and liver function</description>
    <arm_group_label>6 days of oral antibiotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Augmentin</intervention_name>
    <description>Patients will be given 6 days of oral antibiotics based on local biograms, patient allergies and renal and liver function</description>
    <arm_group_label>6 days of oral antibiotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bactrim</intervention_name>
    <description>Patients will be given 6 days of oral antibiotics based on local biograms, patient allergies and renal and liver function</description>
    <arm_group_label>6 days of oral antibiotics</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males aged 35 to 90 yo with no racial or ethnic restrictions and a diagnosis of&#xD;
             erectile dysfunction.&#xD;
&#xD;
          2. Males clinically indicated for de-novo InhibiZonetm coated AMS 700 devices IPP&#xD;
             placement procedure per local clinical guidelines who have elected to pursue penile&#xD;
             prosthesis as an ED treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with indwelling foreign body in the urinary tract &gt; 24 hours prior to the&#xD;
             procedure (i.e. foley catheter). Patients using clean intermittent catheterization&#xD;
             will not be excluded.&#xD;
&#xD;
          2. Prior history of or current symptomatic urethral stricture.&#xD;
&#xD;
          3. History of cystitis caused by Tuberculosis.&#xD;
&#xD;
          4. Active Cytoxan/cyclophosphamide therapy or immunosuppressive systemic chemotherapy.&#xD;
&#xD;
          5. Prior augmentation cystoplasty or cystectomy.&#xD;
&#xD;
          6. Systemic neuromuscular disease known to affect the lower urinary tract such as Spinal&#xD;
             Cord Injury, Multiple Sclerosis or other condition leading to neurogenic bladder.&#xD;
&#xD;
          7. Antibiotic use within the past 1 week or need for antibiotic management immediately&#xD;
             prior to the study.&#xD;
&#xD;
          8. Cases where patients have had a prior penile prosthesis.&#xD;
&#xD;
          9. Any protected population (i.e. Prisoners)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah Faris, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago Department of Surgery</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sarah Faris, MD</last_name>
    <phone>773-702-2573</phone>
    <email>sfaris@surgery.bsd.uchicago.edu</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 30, 2021</study_first_submitted>
  <study_first_submitted_qc>October 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2021</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Erectile Dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Amoxicillin-Potassium Clavulanate Combination</mesh_term>
    <mesh_term>Trimethoprim, Sulfamethoxazole Drug Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>We will share individual participant data that is de-identified available to all qualified investigators</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Upon publication of the major manuscript to be generated from this study. Data will be deposited in an appropriate major database</ipd_time_frame>
    <ipd_access_criteria>All qualified investigators who sign appropriate data use agreements with the University of Chicago</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

